Hostname: page-component-5c6d5d7d68-vt8vv Total loading time: 0.001 Render date: 2024-08-16T19:52:10.689Z Has data issue: false hasContentIssue false
  • English
  • Français

The Pharmacology of Reversible Monoamine Oxidase Inhibitors

Published online by Cambridge University Press:  06 August 2018

R. Amrein ,
S.R. Allen ,
T.W. Guentert ,
D. Hartmann ,
T. Lorscheid ,
M.-P. Schoerlin  and
D. Vranesic
R. Amrein
Affiliation:
F. Hoffmann-La Roche Ltd, Basel, Switzerland
S.R. Allen
Affiliation:
F. Hoffmann-La Roche Ltd, Basel, Switzerland
T.W. Guentert
Affiliation:
F. Hoffmann-La Roche Ltd, Basel, Switzerland
D. Hartmann
Affiliation:
F. Hoffmann-La Roche Ltd, Basel, Switzerland
T. Lorscheid
Affiliation:
F. Hoffmann-La Roche Ltd, Basel, Switzerland
M.-P. Schoerlin
Affiliation:
F. Hoffmann-La Roche Ltd, Basel, Switzerland
D. Vranesic
Affiliation:
F. Hoffmann-La Roche Ltd, Basel, Switzerland
Get access Rights & Permissions [Opens in a new window]

Abstract

The older monoamine oxidase inhibitors (MAOIs) are mechanism-based, irreversible inhibitors of MAO; most inhibit both the A and B forms of MAO. Several of the drugs are hydrazine derivatives which have non-specific effects other than MAO inhibition. These properties convey disadvantages, which may be seen as serious, though infrequent, adverse events — the ‘cheese effect’, hepatotoxicity, amphetamine-like activity, orthostatic hypotension and anticholinergic effects. New, reversible MAOIs stem from a variety of chemical classes and are more specific in their effects, with relatively rapid onset of action, direct relationship between plasma concentration and pharmacological effect, and no prolonged carry-over phenomena.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 155 , Issue S6: Depression and Reversible Monoamine Oxidase Inhibitors-New Perspectives , October 1989 , pp. 66 - 71
Copyright
Copyright © 1989 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abeles, R.J. & Maycock, A.L. (1976) Suicide enzyme inactivators. Accounts of Chemical Research, 9, 313–319.Google Scholar
Anand, R. & Wesnes, K.A. (1989) Moclobemide, a reversible MAO inhibitor possesses cognition enhancing effects in humans. In Alzheimer's Disease: Advances in Basic Research and Therapies. Proceedings of the Fifth Meeting of the International Study Group on the Pharmacology of Memory Disorders Associated with Aging. Zurich, Switzerland, 20–22/01/89. Cambridge, Massachussets: Centre for Brain Sciences and Metabolism Charitable Trust.Google Scholar
Banghart, H. (1958) Effect of marsilid on symptoms of some of the rheumatic diseases. Journal of Clinical and Experimental Psychopathology and Quarterly Review of Psychiatry and Neurology, 19 (Suppl. 1), 114–122.Google Scholar
Bateman, J. (1958) The role of marsilid in patients with far advanced cancer. Journal of Clinical and Experimental Psychopathology and Quarterly Review of Psychiatry and Neurology, 19 (Suppl. 1), 123–125.Google ScholarPubMed
Bieck, P.R. & Antonin, K.-H. (1982) Monoamine oxidase inhibition by tranylcypromine: assessment in human volunteers. European Journal of Clinical Pharmacology, 22, 301–308.Google Scholar
Bieck, P.R., Antonin, K.-H., Cremer, G., et al (1984) Tyramine pressor effects of CGP 11305A in comparison to tranylcypromine after prolonged treatment of human volunteers. In Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors (eds Tipton, K.F., Dostert, P. & Strolin Benedetti, M.). London: Academic Press, pp. 505–513.Google Scholar
Bosworth, D.M. (1958) Discussion of the history of marsilid. Journal of Clinical and Experimental Psychopathology and Quarterly Review of Psychiatry and Neurology, 19 (Suppl. 1), 11–26.Google ScholarPubMed
Burkard, W.P., Bonetti, E.P., Da Prada, M., et al (1989) Pharmacological profile of moclobemide, a short acting and reversible inhibitor of monoamine oxidase type A. Journal of Pharmacology and Experimental Therapeutics, 248, 391–399.Google Scholar
Carrier, E., Lang, F. & Pellet, J. (1982) Méchanisms d'action supposés des antidepresseurs. Hypothés biochimique. Acta Psychiatrica, 4, 147–157.Google Scholar
Da Prada, M., Kettler, R., Keller, H.H., et al (1989) Neurochemical profile of moclobemide, a short acting and reversible inhibitor of monoamine oxidase type A. Journal of Pharmacology and Experimental Therapeutics, 248, 400–414.Google Scholar
Davis, W.A. (1958) The history of marsilid. Journal of Clinical and Experimental Psychopathology and Quarterly Review of Psychiatry and Neurology, 19, (Suppl. 1), 1–5.Google ScholarPubMed
Dourish, C.T., Dewar, K.M., Dyck, L.E., et al (1983) Potentiation of the behavioural effects of the antidepressant phenelzine by deuterium substitution. Psychopharmacology, 81, 122–125.Google Scholar
Felner, A.E. & Waldmeier, P.C. (1979) Cumulative effects of irreversible MAO inhibitors in vivo. Biochemical Pharmacology, 28, 995–1002.CrossRefGoogle ScholarPubMed
Helmkamp, G., Rando, R., Brock, D., et al (1968) β-hydroxydecanoyl thiolester dehydrase. Specificity of substrates and acetylenic inhibitors. Journal of Biological Chemistry, 243, 3229–3231.Google Scholar
Koulu, M., Scheinia, M., Kaartinen, A., et al (1989) Inhibition of monoamine oxidase by moclobemide: effects of monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. British Journal of Clinical Pharmacology, 27, 243–255.CrossRefGoogle ScholarPubMed
Kummer, J., Gündel, L. & Lorscheid, T. (1989) Efficacy and safety of moclobemide (150–300 mg) compared to maprotiline (75–150 mg) in the treatment of geriatric depressed patients. (To be published.)Google Scholar
Lascelles, R.J. (1966) Atypical facial pain and depression. British Journal of Psychiatry, 112, 651–666.Google Scholar
Mallinger, A.G., Edwards, D.J., Himmelhock, J.M., et al (1986) Pharmacokinetics of tranylcypromine in patients who are depressed: relationship to cardiovascular effects. Clinical Pharmacology and Therapeutics, 40, 444–450.CrossRefGoogle ScholarPubMed
Martin, J.R., Schaffner, R., Rumennik, L., et al (1989) Cognitive performance enhancing effects of the reversible MAO inhibitor moclobemide in animals. In Alzheimer's Disease: Advances in Basic Research and Therapies. Proceedings of the Fifth Meeting of the International Study Group on the Pharmacology of Memory Disorders Associated with Aging. Zurich, Switzerland. 20–22/01/89. Cambridge, Massachussets: Centre for Brain Sciences and Metabolism Charitable Trust.Google Scholar
Murphy, D.L. (1978) Substrate-selective monoamine oxidase-inhibitor, tissue, species and functional differences. Biochemical Pharmacology, 27, 1889–1893.Google Scholar
Paech, C., Salach, J.I. & Singer, T.P. (1980) Suicide inactivation of monoamine oxidase by transphenylcyclopropylamine. Journal of Biological Chemistry, 255, 2700–2704.Google Scholar
Postma, J.U. & Vranesic, D. (1985) Moclobemide in the treatment of depression in demented geriatric patients. Acta Therapeutica, 11, 1–4.Google Scholar
Rabkin, J., Quitkin, F., Harrison, W., et al (1984) Adverse reactions to monoamine oxidase inhibitors. Part I. A comparative study. Journal of Clinical Psychopharmacology, 4, 270–278.Google Scholar
Robinson, D.S. & Kurtz, N.M. (1978) Monoamine oxidase inhibiting drugs: pharmacologic and therapeutic issues. In Psychopharmacology: The Third Generation of Progress (ed. Meltzer, H. Y.). New York: Raven Press.Google Scholar
Schläppi, B. (1985) The lack of hepatotoxicity in the rat with the new and reversible short-acting MAO-A inhibitor moclobemide — in contrast to iproniazid. Arzneimittel Forschung/Drug Research, 35, 800–803.Google Scholar
Schoerlin, M.-P. & Guentert, T.W. (1989) Pharmakokinetik und Metabolismus reversibler MAO-A Hemmer beim Menschen. Psychiatrische Praxis (in press).Google Scholar
Schoerlin, M.-P., Mayersohn, M., Korn, A. & Eggers, H. (1987) Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects. Clinical Pharmacology and Therapeutics, 42, 395–404.Google Scholar
Silverman, R.B. (1983) Mechanism of inactivation of monoamine oxidase by trans-2-phenylcyclopropylamine and the structure of the enzyme inactivator adduct. Journal of Biological Chemistry, 258, 14766–14769.Google Scholar
Silverman, R.B. & Yamasaki, B. (1984) Mechanism-based inactivation of mitochondrial monoamine oxidase by N-(1-methylcyclopropyl) benzylamine. Biochemistry, 23, 1322–1332.Google Scholar
Silverman, R.B. & Zieske, P.A. (1985) Mechanism of inactivation of monoamine oxidase by 1-phenylcylcopropylamine. Biochemistry, 24, 2128–2138.Google Scholar
Stabl, M., Biziere, K., Schmid-Burgk, W., et al (1989) Review of comparative trials: moclobemide vs tricyclic antidepressants and vs placebo in depressive states. Journal of Neural Transmission, 28, (Suppl.) (in press).Google Scholar
Tollefson, G.D. (1983) Monoamine oxidase inhibitors: a review. Journal of Clinical Psychiatry, 44, 280–288.Google ScholarPubMed
Walsh, C.T. (1984) Suicide substrates, mechanism based inactivators: recent developments. Annual Review of Biochemistry, 53, 493–535.CrossRefGoogle ScholarPubMed
Wesnes, K.A., Simpson, P.M., Christmas, L., et al (1989) The effects of moclobemide on cognition. Psychopharmacology, 96 (in press).Google Scholar
Zimmermann, H.J. & Ishak, K.G. (1987) The hepatic injury of monoamine oxidase inhibitors. Journal of Clinical Psychopharmacology, 7, 211–213.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.